Stock 8432 TSH BIOPHARM CORPORATION LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials TSH Biopharm Corporation Limited

Equities

8432

TW0008432006

Pharmaceuticals

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
60.3 TWD +2.20% Intraday chart for TSH Biopharm Corporation Limited +10.24% +19.88%
Mar. 11 TSH Biopharm Corporation Limited Announces Directorate Changes on April 1, 2024 CI
Mar. 11 TSH Biopharm Corporation Limited Appoints Jung-Liang Kao as CFO on April 1, 2024 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 2,792 3,014 2,262 1,709 1,826 1,931
Enterprise Value (EV) 1 2,062 2,336 1,545 979.9 1,104 1,167
P/E ratio 48.5 x 35.4 x 36.8 x 36.3 x 29.5 x 31.2 x
Yield 2.2% 2.29% 3.06% 3.37% 3.36% 2.54%
Capitalization / Revenue 5.41 x 5.94 x 5.05 x 4.13 x 3.93 x 2.38 x
EV / Revenue 4 x 4.6 x 3.45 x 2.37 x 2.38 x 1.44 x
EV / EBITDA 30.6 x 38.1 x 19.4 x 16.1 x 15.9 x 15 x
EV / FCF 52.6 x 58.7 x -1,018 x 15.6 x 29.1 x 133 x
FCF Yield 1.9% 1.7% -0.1% 6.4% 3.44% 0.75%
Price to Book 2.49 x 2.68 x 2.01 x 1.58 x 1.71 x 1.74 x
Nbr of stocks (in thousands) 38,398 38,398 38,398 38,398 38,398 38,398
Reference price 2 72.70 78.50 58.90 44.50 47.55 50.30
Announcement Date 4/1/19 3/20/20 3/24/21 3/28/22 3/10/23 2/28/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 515.6 507.7 447.9 413.5 464.4 810.9
EBITDA 1 67.49 61.36 79.66 60.87 69.39 77.65
EBIT 1 61.96 56.2 74.3 55.62 63.2 63.63
Operating Margin 12.02% 11.07% 16.59% 13.45% 13.61% 7.85%
Earnings before Tax (EBT) 1 65.91 103.4 77.23 61.55 76.99 76.09
Net income 1 57.78 85.33 61.57 47.11 61.89 61.99
Net margin 11.21% 16.81% 13.75% 11.39% 13.33% 7.64%
EPS 2 1.500 2.220 1.600 1.227 1.610 1.610
Free Cash Flow 1 39.18 39.83 -1.518 62.7 37.94 8.751
FCF margin 7.6% 7.85% -0.34% 15.16% 8.17% 1.08%
FCF Conversion (EBITDA) 58.05% 64.91% - 103% 54.67% 11.27%
FCF Conversion (Net income) 67.8% 46.68% - 133.09% 61.29% 14.12%
Dividend per Share 2 1.600 1.800 1.800 1.500 1.600 1.280
Announcement Date 4/1/19 3/20/20 3/24/21 3/28/22 3/10/23 2/28/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 729 678 717 729 722 765
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 39.2 39.8 -1.52 62.7 37.9 8.75
ROE (net income / shareholders' equity) 5.1% 7.6% 5.47% 4.26% 5.75% 5.24%
ROA (Net income/ Total Assets) 3.1% 2.83% 3.73% 2.9% 3.4% 2.81%
Assets 1 1,867 3,017 1,653 1,626 1,821 2,210
Book Value Per Share 2 29.20 29.30 29.30 28.20 27.80 28.80
Cash Flow per Share 2 5.630 5.840 10.30 9.950 10.50 15.00
Capex 1 5.89 3 1.92 0.38 5.01 5.38
Capex / Sales 1.14% 0.59% 0.43% 0.09% 1.08% 0.66%
Announcement Date 4/1/19 3/20/20 3/24/21 3/28/22 3/10/23 2/28/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
TSH BIOPHARM CORPORATION LIMITED Stock TSH Biopharm Corporation Limited
+19.88% 70.98M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 8432 Stock
  4. Financials TSH Biopharm Corporation Limited